Abzena, Baylor Scott & White Research Institute deal
Abzena and the institute formed JV Denceptor Therapeutics Ltd. to develop immunotherapies against cancer and autoimmune diseases using the institute’s dendritic cell receptor-targeting antibodies, which Abzena will humanize using its Composite Human Antibody technology. Denceptor has an option to exclusively license the institute’s antibodies, with a sublicense to the humanized versions of the antibodies created by Abzena.
The JV’s lead product is an unnamed immunotherapy targeting HPV E6 and E7 proteins for head and neck cancer and other HPV-associated malignancies. Denceptor will operate as a virtual business and outsource development and manufacturing. Abzena declined to disclose licensing and financial terms, and the institute did not respond to inquiries. ...